Influence of retirement on nonadherence to medication for hypertension and diabetes

Mika Kivimäki PhD, G. David Batty PhD, Mark Hamer PhD, Hermann Nabi PhD, Maarit Korhonen PhD, Risto Huupponen PhD, Jaana Pentti MSc, Tuula Oksanen PhD, Ichiro Kawachi PhD, Marianna Virtanen PhD, Hugo Westerlund PhD, Jussi Vahtera PhD

Abstract

Background: The extent to which common life transitions influence medication adherence among patients remains unknown. We examined whether retirement is associated with a change in adherence to medication in patients with hypertension or type 2 diabetes.

Methods: Participants in the Finnish Public Sector study were linked to national registers. We included data for the years 1994–2011. We identified and followed 3468 adult patients with hypertension and 412 adult patients with type 2 diabetes for medication adherence for the 3 years before their retirement and the 4 years after their retirement (mean follow-up 6.8 yr). Our primary outcome was proportion of patients with poor adherence to medication, which we defined as less than 40% of days covered by treatment. We determined these proportions before and after retirement using data from filled prescriptions.

Results: The preretirement prevalence of poor adherence to medication was 6% in men and women with hypertension, 2% in men with diabetes and 4% in women with diabetes. Among men, retirement was associated with an increased risk of poor adherence to both antihypertensive agents (odds ratio [OR] 1.32, 95% confidence interval [CI] 1.03–1.68) and antidiabetic drugs (OR 2.40, 95% CI 1.37–4.20). Among women, an increased risk of poor adherence was seen only for antihypertensive agents (OR 1.25, 95% CI 1.07–1.46). Similar results were apparent for alternative definitions of poor adherence. Our results did not differ across strata of age, socioeconomic status or comorbidity.

Interpretation: We found a decline in adherence to medication after retirement among men and women with hypertension and men with type 2 diabetes. If these findings can be confirmed, we need randomized controlled trials to determine whether interventions to reduce poor adherence after retirement could improve clinical outcomes of treatments for hypertension and diabetes.

Cardiovascular diseases are the leading cause of death worldwide, and diabetes is projected to be in the top 4 most common causes of death in high-income countries by 2030. Modern antihypertensive medications can substantially reduce the risk of vascular events, and antidiabetic drugs are effective in decreasing diabetes complications. Unfortunately, poor adherence to a medication regimen is common and substantially hampers the effectiveness of these therapies. Identifying factors that predict adherence is of importance to public health.

Much of the research on medication adherence has focused on patient demographic factors and medical history, characteristics of physicians and pharmacists, and facilitation or barrier creation by health care systems. In addition, several trials have been designed to increase adherence though informational, behavioural and motivational strategies and by simplifying dosing regimens. In contrast, surprisingly little is known about the extent to which common life transitions affect adherence to treatment. Retirement is a particularly relevant life transition, because it coincides with various changes in daily routines that potentially affect the continuity of treatment. In addition, retirement is associated with a perception of reduced symptoms of ill health, which might further increase the likelihood of neglecting to follow prescribed treatment regimens.

We employed multiple repeat measurements of filled prescriptions for antihypertensive and antidiabetic medications, both before and after retirement, to examine whether retirement might increase nonadherence among patients with hypertension or type 2 diabetes.
Methods

Study population and design
We used data from the Finnish Public Sector Study, which followed a cohort of 151,901 employees of local government in 10 towns and 21 public hospitals.17 These employees cover a wide range of occupational groups, from city mayors to semiskilled cleaners, the largest groups being nurses and teachers. The sex and age distribution of the members of the cohort correspond to those of all Finnish public sector employees (75% v. 77% women; mean age 44 v. 45 yr). A detailed description of the Finnish Public Sector Study and its context is provided in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.122012/-/DC1).

We linked the cohort members to national prescription and health registers from 1994 to 2011 through the unique personal identification codes assigned to all permanent residents of Finland. Data linkage to registers was successful for all members of the cohort. This study was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa.

Assessment of adherence to treatment
At the time of the study, all prescriptions were written by a physician. The Social Insurance Institution reimbursed 70%–100% of the costs of antihypertensive and antidiabetic drugs for patients granted special reimbursement, including the participants of the present study. We followed participants for adherence to treatment from 3 years before their retirement to up to 4 years after (the observation period). We used days covered by filled prescriptions to assess adherence to treatment, a valid measure of medical adherence in a closed pharmacy system, such as in Finland.19 We defined poor medication adherence as less than 40% of days covered by treatment; we performed subsidiary analyses with alternative cut-offs of 20%, 30%, 50%, 60%, 70% and 80%.10,19,20

We obtained data on all filled prescriptions of antihypertensive and antidiabetic drugs reimbursed to participants between Jan. 1, 1994, and Dec. 31, 2011, from the Social Insurance Institution Drug Prescription Register. This register contains data on all patients who have been granted reimbursement for medications in Finland, including antihypertensive and antidiabetic drugs, with the date on which the permission was granted (diagnostic details in Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.122012/-/DC1).

We used a validated method, based on defined daily doses dispensed, to calculate the number of days for which patients had medication available at each year of follow-up (Appendix 2).18

Other variables
Preretirement covariates included sex, age at retirement, socioeconomic status, depression and cardiovascular comorbidity. We obtained data on sex and socioeconomic status (i.e., manual v. nonmanual labour) from the employers’ registers. An additional indicator for socioeconomic status was size of residence (≤ 80 v. ≥ 80 m²), obtained from the Population Register Centre. We used the Finnish Hospital Discharge Register and the Social Insurance Institution registers to determine depression status (Appendix 2) and comorbid cardiovascular disease (at least 1 of coronary artery disease, coronary insufficiency, cardiac arrhythmia or cerebrovascular disease). Validation studies show the Finnish Hospital Discharge register to contain about 95% of all discharges, and records are correct in at least 95% of the dis-
Table 1: Baseline characteristics of the study population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients with hypertension (n = 3468)</th>
<th>Patients with type 2 diabetes (n = 412)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up, yr, mean ± SD</td>
<td>6.8 ± 0.1</td>
<td>6.7 ± 0.3</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>981 (28.3)</td>
<td>179 (43.4)</td>
</tr>
<tr>
<td>Female</td>
<td>2487 (71.7)</td>
<td>233 (56.6)</td>
</tr>
<tr>
<td>Age at retirement, yr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 62</td>
<td>1900 (54.8)</td>
<td>203 (49.3)</td>
</tr>
<tr>
<td>≥ 62</td>
<td>1568 (45.2)</td>
<td>209 (50.7)</td>
</tr>
<tr>
<td>Occupational group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonmanual labour</td>
<td>2317 (67.0)</td>
<td>252 (61.2)</td>
</tr>
<tr>
<td>Manual labour</td>
<td>1144 (33.0)</td>
<td>159 (38.8)</td>
</tr>
<tr>
<td>Size of residence, m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 80</td>
<td>1673 (48.2)</td>
<td>207 (50.2)</td>
</tr>
<tr>
<td>≥ 80</td>
<td>1795 (51.8)</td>
<td>205 (49.8)</td>
</tr>
<tr>
<td>Type of retirement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statutory</td>
<td>2337 (67.4)</td>
<td>249 (60.4)</td>
</tr>
<tr>
<td>For health reasons</td>
<td>1131 (32.6)</td>
<td>163 (39.6)</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2873 (82.8)</td>
<td>349 (84.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>595 (17.2)</td>
<td>63 (15.3)</td>
</tr>
<tr>
<td>Comorbid CVD†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>3029 (87.3)</td>
<td>343 (83.3)</td>
</tr>
<tr>
<td>Yes</td>
<td>439 (12.7)</td>
<td>69 (16.7)</td>
</tr>
</tbody>
</table>

Note: CVD = cardiovascular disease, SD = standard deviation.
*Unless otherwise indicated.
†Coronary insufficiency, coronary heart disease, cardiac arrhythmia and cerebrovascular disease.

Table 2: Rates of poor medication adherence among study participants before and after retirement

<table>
<thead>
<tr>
<th>Population</th>
<th>Poor adherence, %*</th>
<th>Adjusted† OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before retirement</td>
<td>After retirement</td>
</tr>
<tr>
<td>Patients with hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>5.6</td>
<td>7.2</td>
</tr>
<tr>
<td>Women</td>
<td>6.1</td>
<td>7.5</td>
</tr>
<tr>
<td>Patients with type 2 diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>2.3</td>
<td>5.2</td>
</tr>
<tr>
<td>Women</td>
<td>3.8</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Note: CI = confidence interval, OR = odds ratio.
*Defined as less than 40% of days covered by treatment.
†Repeated measures regression with generalized estimating equation adjusted for sex, age at retirement and calendar year.

Charges compared with the corresponding medical records.22,23 Dates of death were obtained from the Finnish Causes of Death Register, which has received high ranking with respect to its reliability and accuracy in international comparisons.24

Statistical analysis
We analyzed a 7-year observation period including the 3 years before and the 4 years after the date of retirement. Periods during which participants stayed in hospital were excluded from follow-up. Participants were censored at death. We stratified data by sex and performed analyses separately for poor adherence in relation to hypertension and diabetes medications. The participants who received treatment for both hypertension and diabetes were included in both sets of analyses. We calculated annual prevalence estimates and prevalence ratios of poor medication adherence and their 95% confidence intervals (CIs) using a repeated-measures log-binomial regression with the generalized estimating equation (GEE) method and autoregressive correlation structure. GEE takes into account the intrapatient correlation between measurements and is not sensitive to missing measurements.25 We used an interrupted time series design within the time series analysis to model the mean prevalence of medication adherence before and after retirement. We assigned a weight of 0.33 for each of the 3 preretirement years of follow-up and a weight of 0.25 for each of the 4 postretirement years. We computed odds ratios (ORs) and their 95% CIs for postretirement adherence compared with preretirement adherence. We adjusted the models for age at retirement and, to eliminate period effects, for calendar year.

To examine whether there were differences in the associations according to various subgroups (ie, by age group, socioeconomic status, type of retirement [statutory v. for ill health], depression and cardiovascular comorbidity), we calculated the prevalence ratio of medication adherence after retirement compared with that before retirement from models including the subgroup, time, calendar year, age at retirement and the interaction term “subgroup characteristic × time.”

We performed all statistical analyses using SAS 9.2.

Results
We identified 25 535 people who retired between 1996 and 2010, 21 052 of whom were alive at least 1 year after their retirement and were included in our analyses. Complete prescription data were available for all included participants.
Of the 21,052 participants, 3,889 had hypertension before their retirement, and 611 had type 2 diabetes before their retirement. We only included patients with hypertension \((n = 3,468)\) or type 2 diabetes \((n = 412)\) whose diagnoses were made before the start of our observation period; thus, we excluded 421 patients with hypertension and 199 patients with diabetes whose diagnoses were made after the start of our observation period.

Of the 3,880 included participants, 2,720 (70.1\%) were female, corresponding the sex distribution of the overall cohort (Table 1). Median age at retirement for participants was 61 years (interquartile range 55–64 yr). The mean follow-up was 6.8 years for patients with hypertension and 6.7 years for patients with diabetes.

Among men with hypertension, the adjusted prevalence of poor adherence to antihypertensive medication was 5.6% during the 3 years of follow-up before their retirement and 7.2% during the 4 years of follow-up after their retirement (Table 2). The corresponding adjusted OR was 1.32 (95% CI 1.03–1.68, postretirement v. preretirement). We saw a similar trend in relation to antidiabetic medication: the adjusted prevalence of poor adherence was 2.3% before retirement and 5.2% after retirement, with an adjusted OR of 2.40 (95% CI 1.37–4.20). Among women, the ratio for poor adherence to antihypertensive medication was 1.25 (95% CI 1.07–1.46), with a preretirement prevalence of poor adherence of 6.1% and a postretirement prevalence of 7.5%.

We saw no significant change in adherence in relation to antidiabetic medication for women before and after retirement.

More-detailed year-by-year trajectories of poor medication adherence, adjusted for age at retirement and calendar year, confirmed that the annual prevalence of poor adherence to antihypertensive medication was higher for each year of postretirement follow-up than for preretirement follow-up (Appendix 3, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.122012/-/DC1). For men, but not women, a similar pattern was seen for annual prevalences of poor adherence to antidiabetic medication.

Among men, we saw a postretirement increase in prevalence of poor adherence to antihy-
pertensive and antidiabetic medications in younger and older employees, across occupational groups, sizes of residence and types of retirement, and among those with and without comorbidity (Figure 1 and Appendix 4, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.122012/-/DC1). The results for women with hypertension were similar (Figure 2 and Appendix 4), with the exception that poor adherence did not increase substantially after retirement among those with comorbid cardiovascular conditions. Nonetheless, there was no statistical evidence to suggest that the postretirement increase in poor adherence would differ between subgroups (all $p$ for interaction > 0.07).

Repeating our main analysis using alternative cut-offs for poor adherence showed postretirement increases in poor adherence among men and women with hypertension for all alternative definitions, ranging from less than 20% of days to less than 80% of days covered by treatment. For example, when poor adherence was defined as less than 80% of days covered by filled prescriptions, adherence was 19.9% before retirement and 24.1% after retirement for men with hypertension (adjusted OR 1.29, 95% CI 1.11–1.49) (Table 3). A postretirement increase in poor adherence was also seen in men with type 2 diabetes when poor adherence was defined as less than 20%, 30%, 40% or 50% of days covered by treatment.

**Interpretation**

For men and women with hypertension and men with type 2 diabetes, retirement was linked to 1.3- to 2.4-fold increases in poor medication adherence. We saw no significant difference in this adherence pattern between age groups, socioeconomic strata, or patients with and without depression or comorbid cardiovascular disease. These patterns suggest that our findings were robust and not limited to a specific subgroup. Our results were also robust when we used alternative definitions of poor adherence.

Major life changes other than retirement have previously been shown to be associated with a decline in medication adherence. The reasons for reduced postretirement adherence are not known. However, several recent studies have shown a long-term improvement in perceived health after statutory retirement. Given that hypertension and type 2 diabetes are often asymptomatic, a perception of reduced symptoms of ill health after retirement may result in a sense of false security encouraging reduced medication use. Other plausible explanations include the loss of the daily routines imposed by work leading to increased forgetfulness, and the transition from occupational to nonoccupational health care interrupting patients’ interactions with their general practitioners, potentially affecting the continuity of drug treatments. Such an interruption could cause a temporary decline in adherence, although our year-by-year analysis suggests that the increase in poor adherence persisted for the entire postretirement follow-up period. Furthermore, retirement is related to a reduction in income, which might lead patients to prioritize other purchases over their medication. However, this explanation seems unlikely in the current context, because the postretirement increase in nonadherence was seen across socioeconomic strata. Indeed, costs related to antihypertensive and antidiabetic drugs are relatively low and, in Finland, filled prescriptions are mostly or fully reimbursed by national health insurance, similar to insurance schemes for older adults in other Scandinavian countries, the United Kingdom, the United States and Canada.
Strengths and limitations

Finland and the other Scandinavian countries are particularly favourable settings for these kinds of studies, because they are under single universal prescription reimbursement systems with fully or nearly fully comprehensive prescription registers.11 This circumstance offers a rare possibility to monitor individual patient adherence to medication in day-to-day clinical practice. However, our results have some limitations.

This study did not include medical examinations. The diagnoses of hypertension and type 2 diabetes came from treating physicians and were confirmed by an external national committee granting special reimbursement for medication. Although pharmacy refill records are objective measures and collected routinely, they include only information on purchases and do not represent a measure of whether the patients actually took the medications. Thus, it is possible that we have slightly overestimated adherence. However, a substantial bias to relative differences in participants’ adherence after retirement compared with before retirement is unlikely.

We determined the proportion of days covered by a medication for hypertension or diabetes using the daily defined doses, which is a valid, although not exact, method.18 Among patients with type 2 diabetes, adherence to injected insulin is, if anything, higher than adherence to medications taken orally. In this study, for example, the prevalence of poor adherence was 3.1% in men and 5.0% in women for medications taken orally. In this study, for example, the prevalence of poor adherence was 3.1% in men and 5.0% in women for medications taken orally, but only 1.6% among patients using insulin. Given that insulin treatment relates to a more advanced stage of the disease and thus is more common after retirement, this may have slightly masked the adverse effect of retirement on non-adherence among the participants with diabetes.

Conclusion

We found an increase in the prevalence of poor adherence to medication after retirement among men and women with hypertension and men with type 2 diabetes. These findings suggest that retirement may increase medication nonadherence, a timely issue given that the proportion of people aged 65 years or older is growing rapidly. Further research is needed to determine the generalizability of our findings across multiple settings and in other populations. In addition, randomized controlled trials are needed to determine whether interventions to tackle this issue would improve clinical outcomes of treatment.

References

4. Effect of intensive blood-glucose control with metformin on

Affiliations: Department of Epidemiology and Public Health (Kivimäki, Batty, Hamer), University College London, London, UK; Finnish Institute of Occupational Health and University of Helsinki (Kivimäki, Pentti, Oksanen, Virtanen, Vahtera), Helsinki, Finland; Centre for Cognitive Aging and Cognitive Epidemiology (Batty), University of Edinburgh, Edinburgh, UK; Institut national de la santé et de la recherche médicale (Nabi), Centre for Research in Epidemiology and Population Health, Villejuif, France; Department of Pharmacology (Korhonen, Huupponen), Drug Development and Therapeutics, University of Turku, and Turku University Hospital, Turku, Finland; Harvard School of Public Health (Kawachi), Boston, Mass.; Stress Research Institute (Westerlund), Stockholm University, Stockholm, Sweden; Department of Public Health (Vahtera), University of Turku, and Turku University Hospital, Turku, Finland

Contributors: Mika Kivimäki, Jussi Vahtera and Jaana Pentti designed the hypothesis. Mika Kivimäki wrote the first draft. Jussi Vahtera and Jaana Pentti analyzed the data. All of the authors contributed to the concept and design of the study and the critical revision of the manuscript for important intellectual content, and approved the final version submitted for publication.

Funding: This study was supported by the Academy of Finland, the Finnish Work Environment Fund, Finland, the Social Insurance Institution of Finland and the participating organizations. Mika Kivimäki was supported by the United Kingdom Medical Research Council (K013351), the National Institutes of Health (R01HL036310 and R01AG034454) of the United States, the Finnish Work Environment Fund, and an Economic and Social Research Council professorship, UK. David Batty was supported by a Wellcome Trust Research Fellowship. Mark Hamer was supported by the British Heart Foundation. The sponsors had no role in designing the study, analyzing or interpreting the data, or preparing the manuscript.